Last reviewed 2026-04-23 · How we verify

Saizen® A

Saizen A is a recombinant human growth hormone analogue used to treat growth hormone deficiency.

Saizen A is a recombinant human growth hormone analogue used to treat growth hormone deficiency. Used for Growth hormone deficiency in children.

At a glance

Mechanism of action

Saizen A works by mimicking the action of natural growth hormone in the body, stimulating growth and development in children with growth hormone deficiency. It is administered via injection and has a similar mechanism of action to endogenous growth hormone.

Approved indications

• Growth hormone deficiency in children

Common side effects

• Injection site reaction
• Headache
• Nausea
• Diarrhea
• Fatigue

Key clinical trials

• A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (PHASE3)
• Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders (PHASE3)
• A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
• A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (PHASE1, PHASE2)
• A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics (PHASE2)
• A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
• Effects of Ketone Bodies on Insulin Sensitivity (NA)
• Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.